Introduction
Respiratory syncytial virus (RSV) is a problematic pathogen for all children before age 2 and is the major cause for hospitalization in newborns (1) . Immunity to the virus is incomplete and there is now clear evidence that RSV infections in adults with chronic lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) contribute significantly to exacerbation of these underlying conditions (2) (3) (4) (5) (6) . Infection with RSV can also be fatal in immunocompromised individuals such as bone marrow transplant patients and those with HIV-AIDS (7) . Worldwide, RSV is estimated to infect 34 million individuals annually and result in high mortality in children during the first 2 years of life (8) . The virus is second only to malaria in causing death in early childhood in undeveloped countries (9) . Currently there is no vaccine for the virus and there are no beneficial medications for treatment of infected individuals.
Pulmonary surfactant is a lipid and protein complex secreted at the air liquid interface of the alveolar compartment of the lung, that plays important roles in reducing alveolar surface tension and regulating innate immunity (10) . Recently, several studies have identified significant antiviral activity exerted by the minor anionic pulmonary surfactant phospholipid, palmitoyl-oleoyl phosphatidylglycerol (POPG), against respiratory viruses, including multiple strains of RSV and influenza A viruses (11) (12) (13) . The concentration of POPG and other PG species in the surfactant complex is remarkably high (~10 mg/ml, 12.5 mM) and greatly exceeds that described for any other tissues. In addition to inhibiting viral infection, POPG also antagonizes the activation of Toll-like receptors (TLR) 1, 2, 4 and 6 (14, 15) Pulmonary surfactant also contains a second minor anionic phospholipid, phosphatidylinositol (PI) at concentrations of ~1mg/ml (~1.15 mM) (16) . Previous work has also identified PI as a regulator of TLRs 1, 2, 4,and 6 (14, 15, 17, 18 ).
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The antagonism of TLR4 activation by PI and POPG appears to occur by partially overlapping mechanisms involving the inhibition of CD14 recognition of bacterial lipopolysaccharide (14) .
These previous observations led us to test whether PI could also inhibit RSV infection in vitro and in vivo. The purpose of this study was to determine if PI could: 1) antagonize RSV induced inflammatory cytokine production from epithelial cells, 2) inhibit RSV infection in vitro, 3) directly bind to the virus and disrupt cell surface attachment, 4) block RSV infection in mice, and 5) provide prophylaxis against RSV infection. Our findings demonstrate that POPG and PI have overlapping anti-viral functions in the lung and suggest that PI or structurally related molecules could be useful in preventing and treating RSV infection.
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MATERIAL AND METHODS
Cell culture, Viruses, Reagents
HEp2 cells and BEAS2B cells were obtained from American Type Tissue Culture Collection and cultured as previously described (11) . The human RSV A2 strain (VR-1540) was also obtained from American Tissue Culture Collection. Virus stocks were propagated in HEp2 cell monolayers using Dulbecco's Modified Eagle Medium/Ham's F12 Medium (DMEM/F12: GIBCO) plus 5% bovine growth serum (BGS, Hyclone); and purified using methods previously described (11, 19, 20) . Viral titers and growth were measured using quantitative plaque assays (21) . The Toll-like receptor 5 (TLR5) agonist, flagellin, was purchased from Alexis. Agarose was obtained from MP Biomedicals LLC.
Phospholipids
All phospholipids used in these studies were obtained from Avanti Polar Lipids. The biological source of PI was soybean. The molecular species distribution of the PI used in the experiments was determined by mass spectrometry and consisted of the following molecular ions (mole%) 34:2 (58.4%), 36:2 (14.9%), 36:4 (9.5%), 36:3 (7.8%), 34:3 (6.5%), 36:5 (1.8%). Mass spectrometry experiments (MS and MS/MS) were performed on an AB Sciex QTRAP. An autosampler was used to directly infuse the sample into the mass spectrometer utilizing electrospray ionization in negative ion mode. A Methanol/Acetonitrile/Water (60/20/20, v/v/v) solvent system was used and soybean PI was diluted to 20 ng/µL. MS/MS experiments utilized a Collision Energy = 50 eV. The relative intensities of the molecular ion peaks were used to estimate the mol fraction of molecular species within the mass range of 300-900. these and all other experiments were bath sonicated until they produced a clear solution, and sterilized by filtration prior to addition to cell cultures. At 48hrs after infection, IL-8 secretion into the medium was determined by ELISA (11) . The phospholipid palmitoyl-oleoylphosphatidylcholine (POPC) was used as a negative control lipid (11, 12) .
To rule out non-specific effects of lipids upon the ability of BEAS2B cells to respond to proinflammatory stimuli, the cells were challenged with the Toll-like receptor 5 agonist, flagellin (10 ng/ml), in either the absence, or presence of 200 µg/ml POPG, POPC or PI. After 48hrs the culture supernatants were harvested and IL-8 production was measured by ELISA. Additional control experiments were performed to determine the effects of 200 µg/ml phospholipids upon BEAS2B protein synthesis, by monitoring the incorporation of 3 H leucine into macromolecular pools precipitable by 5% trichloroacetic acid (14) In additional experiments we determined the activity of POPG, PI, POPC and DPPC as inhibitors inoculum and lipids were removed from the wells, which were overlayed with medium containing 0.3% agarose. After 6 days of further incubation the cultures were fixed and stained and the viral plaques were quantified (12, 21) .
RSV binding to solid phase phospholipids and HEp2 cells.
RSV binding to phospholipids was measured using phospholipid solid phases in microtiter wells, as previously described (11, (13) (14) (15) . Phospholipids in 100% ethanol were added in 50 µl aliquots (1.5 nmol lipid), to wells in flat-bottomed microtiter plates (Corning). The ethanol was removed under a stream of warm air, and the wells were hydrated and blocked with solutions of 20mM
Tris pH 7.4, 100mM NaCl, 10mM CaCl 2 , containing 3% BSA and then incubated with varying concentrations of RSV (11, 13) . The binding reactions were conducted at 37°C for 2hr.
Subsequently, the wells were washed three times with the binding buffer. Specific virus binding was detected with horseradish peroxidase (HRP)-conjugated anti-human RSV antibody (1:500) (AbD Serotec) by ELISA, using orthophenylenediamine substrate and measuring absorbance at 450nm (11, 13) .
RSV binding to epithelial cell plasma membrane was detected using monlayers of HEp2 cells or phosphatidic acid (PA)). Following the binding reaction, the monolayers were washed with PBS at 0°C, three times, to remove unattached viruses. The cultures were next harvested by scraping in SDS-PAGE loading buffer and briefly sonicated, and denatured at 95°C, and aliquots were electrophoresed on 8-20% polyacrylamide gels. After electrophoresis the gels were processed for immunoblotting, and viral proteins were detected with HRP-conjugated antihuman RSV antibody (1:500) using enhanced chemiluminescence (22) . The viral G-protein band was chosen for sample comparison and films were scanned and then analyzed using the NIH Image J analysis program (22) .
We also conducted phospholipid interaction experiments with RSV to test for the potential 
PI Turnover in mice
To determine the turnover of instilled PI in vivo, anesthetized mice were inoculated with 150 µg of the lipid in 50 µl of PBS. Subsequently, the mice were euthanized with CO 2 , and 5 serial lavages (1ml each) were performed with buffer (Hanks Buffered Solution (HBSS) containing 0.5mM EGTA and 4.4mM sodium bicarbonate) at 0, 30, 60, 180, and 360 min, after inoculation.
Cells were removed by centrifugation at 200 x g x 5 min, and the supernatant fluid was processed for lipid extraction as previously described (24) . Phospholipid content was determined by measurement of lipid phosphate (25) . Phospholipid classes were analyzed by thin-layer chromatography (TLC) and phosphate determination as previously described (25, 26) . 
RESULTS
PI inhibits IL-8 production induced by RSV in human epithelial cells
POPG is a minor anionic phospholipid constituent of pulmonary surfactant that has previously been shown to inhibit virus-dependent inflammatory cytokine production (11, 22, 27) . In these experiments we investigated whether PI, another minor anionic phospholipid present in pulmonary surfactant, has similar activity. Initially we compared PI and POPG as antagonists of RSV-elicited IL-8 production from BEAS2B epithelial cells (11) . The cells were pretreated with lipids (200 µg/ml) for 1hr, and then infected with RSV (MOI = 0.5), and IL-8 secretion into the culture supernatant was measured at 48hr after infection. As shown in Figure 1A , both POPG and PI inhibit IL-8 production in a dose dependent manner. The IC 50 value for POPG was 11.4 ± 1.7 (µg/ml), and that of PI was 21.9 ± 5.6 (µg /ml). The control lipid, POPC did not have a significant effect on IL-8 production. To exclude any toxic effects of POPG and PI, BEAS2B cells were stimulated with the 10 ng/ml of the TLR5 agonist, flagellin and the response was quantified (11) . Neither POPG (200 µg/ml), nor PI (200 µg/ml) significantly inhibited IL-8 production induced by flagellin (Fig.1B) . As an additional control to evaluate lipid toxicity, cultures were incubated with
PI inhibits RSV infection in vitro
In the next series of experiments we tested the activity of PI as an inhibitor of RSV infection.
The anti-viral activity of PI was quantified by infecting HEp2 cells for 2hrs in either the absence, or presence of the indicated concentrations of PI. Subsequently, the viral inoculum and lipids were removed from the cultures and the cell monolayers were overlayed with agarose. After 5 days the appearance of plaques was quantified. In Figure 1D , the data demonstrate that both PI and POPG potently reduce viral plaque formation in a concentration dependent manner. The activity of PI is comparable to that of POPG, which was previously shown to potently inhibit RSV infection and replication (11) . At concentrations of 200 µg/ml, PI reduces viral infection in vitro by a factor >10 3 . These data demonstrate that PI, like POPG, strongly suppresses RSV infection in vitro. We also performed additional experiments examining 200 µg/ml DPPC as a potential inhibitor of viral infection, because this phospholipid is the most abundant in pulmonary surfactant. The findings from two independent experiments demonstrated that DPPC did not have any significant inhibitory activity upon RSV plaque formation (virus alone = 3 x 10 7 pfu/ml, virus + DPPC = 3.3 x 10 7 pfu/ml, virus + POPG = 3 x 10 3 pfu/ml).
PI binds to RSV with high affinity and blocks viral attachment to epithelial cells
We next sought to elucidate the mechanism by which PI inhibits RSV infection. Previous studies with POPG demonstrated this lipid disrupts RSV infection by direct, high affinity interactions with the virus that block attachment to epithelial cell plasma membranes (11) . We 
PI does not act as a viricidal agent
The data in 
PI suppresses RSV infection in vivo.
We resulted in no detectable IFN-γ in the BALF (11) . We examined the RSV burden present in the left lungs of mice by plaque assay, as previously described (11, 21) . The results shown in Fig.   5D demonstrate that PI reduced viral titers by a factor ~30. As a control condition, in these infection experiments we also inoculated mice with PI alone and the results in Fig. 5A , 5B, and 5C demonstrate that this treatment was without a significant effect on any of the measured parameters.
We also examined the effects of RSV and PI treatment of the mice by quantitative histopathology using light microscopy, which provides a means for comparing tissue damage and inflammation among the different treatment groups. The data in Fig. 5E demonstrate that PI significantly reduces the histological criteria for pulmonary inflammation and infection. Fig. 5F shows representative micrographs of right lung sections for the different experimental conditions applied to the mice. The results show that RSV elicits inflammatory responses and damage to the bronchial and alveolar epithelia that are markedly curtailed by PI treatment. Collectively, the data in Fig. 5 demonstrate that in mice, PI significantly suppresses the effects of RSV infection upon the lung.
Supplemental PI has a relatively long turnover time in mouse lung.
Recently, we reported that supplemental POPG has a relatively short turnover time (t 1/2~4 5min) in the mouse lung and this corresponds to a short prophylaxis window for the use of this phospholipid (13). We performed similar turnover studies with PI in mice using a 150 µg (172 nmol) intranasal inoculum. Following administration of PI, groups of mice were euthanized and lavaged after 0, 30, 60, 180 and 360 min, and the amount of PI recovered in the cell-free BALF was measured, using thin layer chromatography and lipid phosphate determination. (13, 25) .
The data presented in Fig. 6A show that the supplemental PI can be readily recovered and detected in the BALF immediately after the administration. Chemical measurement of PI by phosphate analysis in Fig. 6B , demonstrates that the PI turns over relatively slowly with ~50% of the lipid recoverable at 0 time remaining after 6hrs. Fig. 6C reveals that the pool of introduced PI recoverable from lavage exceeds that of the endogenous pool by ~25-fold immediately after instillation and ~15 fold at 6hrs after instillation. Despite these large changes in BALF lipid composition, the levels of PI used in these experiments did not produce any overt signs of distress in the mice, and the histopathology from the experiments described in Fig. 5 also does not show any signs of adverse effects. A plot of the time dependent loss of PI from the BALF is shown in Fig. 6D and demonstrates an initial rapid turnover followed by slower turnover. The markedly slower turnover phase suggests that PI can persist in the extracellular compartment for extended periods of time.
PI provides significantly longer prophylaxis against RSV than POPG.
The slower turnover rate of PI compared with that previously reported for POPG (13, 22) prompted us to test whether PI would provide improved protection from RSV infection in mice.
In preliminary studies (data not shown) we treated mice with 600 µg of PI at either 6hrs or 3hrs before RSV infection. The 6hrs pretreatment was ineffective, but the 3hrs pretreatment reduced viral plaque numbers recovered from the left lungs by ~50% (data not shown). We next performed in vivo studies using a 600 µg treatment of mice with PI at 2hrs prior to infection with RSV, and the results of these experiments are shown in Fig. 7 . The RSV infection elicited an expected 14-fold increase in cellular infiltrates recoverable in lavage, which was almost completely suppressed by either simultaneous treatment, or pre-treatment with PI (Fig. 7A) .
Likewise, the PI pre-treatment reduced the neutrophil and lymphocyte populations to near control levels (Fig. 7B) . The data in Fig. 7C demonstrate the effects of pre-treatment with PI upon RSV-elicited IFN-γ levels (75% reduction compared to viral infection alone) were not as pronounced as that observed with simultaneous PI treatment, but still demonstrate significant suppression of viral infection. The PI-pretreatment reduced the viral burden in the lungs by 85% (Fig. 7D ) as compared to the 97% suppression effected by simultaneously treatment with PI.
Thus PI prophylaxis provides significant benefit for protecting against RSV infection.
Compared with previous prophylaxis studies using POPG, PI more that doubles the efficacy window for protection against the virus.
Discussion
Pulmonary surfactant is a protein-and lipid rich-complex synthesized by alveolar type 2 cells and secreted onto the air/tissue interface of the alveoli (11, 28) . The presence of these endogenous inhibitors of pulmonary inflammation, and the tolerance of the lung to high pharmacological doses of these lipids, provide provocative evidence that these lipids can be applied pharmacologically in disease situations where destructive tissue inflammation has spiraled out of control, or in the early stages of viral infection.
The studies described in this report further broaden our understanding of the action of pulmonary surfactant PI by demonstrating this minor phospholipid also can act to neutralize RSV. The in vitro experiments demonstrate that PI prevents RSV from engaging signaling processes required for epithelial cell secretion of IL-8, an early alarm cytokine that serves to recruit neutrophils into the lung. In vitro, the IC 50 for PI inhibition of IL-8 secretion is ~22 µg /ml, a level well below the concentration of the lipid within the alveolar compartment (~1mg/ml). One major mechanism by which PI disrupts RSV-elicited proinflammatory signaling is by direct interaction with the virus. Like POPG, PI binds to RSV with high affinity in a concentration dependent and saturable reaction (11, 22) . The high affinity interaction of PI with RSV blocks the attachment of the virus to epithelial cell plasma membrane and consequently, infection. Several molecules have been proposed as receptors for RSV including plasma membrane nucleolin and glycosaminoglycans among others (32) (33) (34) (35) . The inhibition of viral infection in vitro is significant with concentrations of PI of 200 µg/ml reducing infection by a factor of >10 3 .
The inhibitory action of PI upon RSV attachment to epithelial cells shows structural specificity.
Other anionic phospholipids, which are not present in pulmonary surfactant, such as PA and PS, fail to inhibit RSV binding to epithelial cells in vitro. In addition, the zwitterionic phospholipid POPC also fails to alter RSV binding to epithelial cells. Like POPG, the PI molecular species used in this study (derived from soybean) contain unsaturated fatty acids in the diacylglycerol portion of the molecule. However, unsaturated fatty acids are also present in the PS, PA and PC molecular species used in these experiments, so the dominant determinant appears to reside within the polar headgroup of the molecule. In molecular modeling (see Fig. 8 ), the orientation of the phosphodiester bond and two hydroxyls present in the polar headgroup of PG are structurally superimposable upon the phosphodiester bond and hydroxyls in positions 2' and 3' of the PI headgroup ring. The results suggest that anionic character and hydroxyl groups are likely to contribute to the binding interactions between the lipids and virus.
The in vitro activity of PI as an antagonist of RSV infection is recapitulated in vivo using a mouse model of viral infection. When PI is introduced at the same time as RSV, using intranasal inoculation, the viral infection is almost completely abrogated. PI dramatically reduces total cellular infiltration and inflammatory cellular infiltration into the lung, reduces the viral burden by a factor of 30 and prevents the engagement of signaling processes required for IFN-γ production. Collectively, these data demonstrate effective neutralization of RSV in vivo and vitro, and suggest that if PI can be maintained at sufficient levels within the lung for long enough periods of time, it can be used as a therapeutic for arresting an established viral infection.
We also examined the potential role of PI as a preventative against RSV infection. In Fig. 6 we provide evidence that pharmacological supplementation of mice with PI results in significant expansion of the endogenous pool of the lipid, and this expansion appears relatively long-lived.
Approximately 50% of the applied PI dose was retained in the extracellular bronchoalveolar compartment for 6 hrs. This apparently slow turnover of PI corresponded with a significant window of efficacy for the lipid to protect the host from viral infection. When PI was introduced 2hrs prior to RSV infection, the total and inflammatory cellular infiltrates in BALF were reduced to near control levels, the IFN-γ levels were reduced by 75%, and the viral burden within the lung was reduced by 85%. Although the 2hrs pretreatment with PI afforded significant protection against RSV infection, the infectious particles recovered from the lung and the IFN-γ levels indicate that a modest level of viral infection occurred. This anti-viral action of PI is significantly longer than that found for POPG which had a prophylaxis efficacy window of 45min.
In considering the findings of this study it is important to also factor in the differences between mouse and human respiratory physiology. Mice breathe at a rate up to 300/min whereas in human newborns the rate is 25/min. The turnover of pulmonary surfactant constituents is coupled to the respiratory rate. Perhaps this is best illustrated from stable isotope studies of human neonates supplemented with artificial pulmonary surfactant that reveal the t 1/2 for POPG in the lung is ~30hrs. Such data suggest that both POPG and PI administered in pharmacological doses to humans should have significant benefit for both preventing and treating RSV infections.
In summary, our data demonstrate that the minor anionic pulmonary surfactant phospholipid, PI, has potent antiviral activity against RSV, which is a serious respiratory pathogen, without an effective vaccine for prevention. PI binds the virus with high affinity and prevents its attachment to-and infection of-epithelial cells. Pharmacological doses of PI are relatively long-lived in the mouse lung and show better prophylaxis activity than POPG. These findings suggest new pharmacological approaches to both prevention and treatment of RSV in both developed and underdeveloped countries. by guest, on October 30, 2017 
